JP2013501722A - 前立腺癌の処置 - Google Patents

前立腺癌の処置 Download PDF

Info

Publication number
JP2013501722A
JP2013501722A JP2012523949A JP2012523949A JP2013501722A JP 2013501722 A JP2013501722 A JP 2013501722A JP 2012523949 A JP2012523949 A JP 2012523949A JP 2012523949 A JP2012523949 A JP 2012523949A JP 2013501722 A JP2013501722 A JP 2013501722A
Authority
JP
Japan
Prior art keywords
compound
administration
composition
subject
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012523949A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013501722A5 (https=
Inventor
モリソン，ジョディー，ポープ
スタイン，サイ，アーロン
ケースビアー，デイビッド，スコット
Original Assignee
トーカイ ファーマシューティカルズ，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by トーカイ ファーマシューティカルズ，インク． filed Critical トーカイ ファーマシューティカルズ，インク．
Publication of JP2013501722A publication Critical patent/JP2013501722A/ja
Publication of JP2013501722A5 publication Critical patent/JP2013501722A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Reproductive Health (AREA)
  • Physiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2012523949A 2009-08-07 2010-08-05 前立腺癌の処置 Pending JP2013501722A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US23225709P 2009-08-07 2009-08-07
US61/232,257 2009-08-07
US26126509P 2009-11-13 2009-11-13
US61/261,265 2009-11-13
PCT/US2010/044570 WO2011017534A2 (en) 2009-08-07 2010-08-05 Treatment of prostate cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015221564A Division JP2016074687A (ja) 2009-08-07 2015-11-11 前立腺癌の処置

Publications (2)

Publication Number Publication Date
JP2013501722A true JP2013501722A (ja) 2013-01-17
JP2013501722A5 JP2013501722A5 (https=) 2013-09-19

Family

ID=43535282

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012523949A Pending JP2013501722A (ja) 2009-08-07 2010-08-05 前立腺癌の処置
JP2015221564A Pending JP2016074687A (ja) 2009-08-07 2015-11-11 前立腺癌の処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015221564A Pending JP2016074687A (ja) 2009-08-07 2015-11-11 前立腺癌の処置

Country Status (8)

Country Link
US (5) US8791094B2 (https=)
EP (1) EP2461814A4 (https=)
JP (2) JP2013501722A (https=)
KR (1) KR20120056267A (https=)
AU (1) AU2010279398A1 (https=)
BR (1) BR112012002797A2 (https=)
CA (1) CA2770092A1 (https=)
WO (1) WO2011017534A2 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100048524A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
US8785423B2 (en) * 2008-04-14 2014-07-22 University Of Maryland, Baltimore Compositions and methods of inducing endoplasmic reticulum stress response for the treatment of cell proliferative diseases
WO2010091306A1 (en) 2009-02-05 2010-08-12 Tokai Pharmaceuticals Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
UY32730A (es) 2009-06-26 2011-01-31 Novartis Ag Inhibidores de cyp17
WO2011017534A2 (en) 2009-08-07 2011-02-10 Tokai Pharmaceuticals, Inc. Treatment of prostate cancer
AU2012249421B9 (en) 2011-04-28 2015-10-22 Novartis Ag 17alpha-hydroxylase/C17,20-lyase inhibitors
BR112014001440A2 (pt) * 2011-07-18 2017-02-21 Tokai Pharmaceuticals Inc novas composições e métodos para o tratamento de câncer de próstata
US20130203615A1 (en) * 2011-08-05 2013-08-08 Gen-Probe Incorporated Antiandrogen therapy monitoring methods and compositions
WO2013071177A1 (en) * 2011-11-10 2013-05-16 Tokai Pharmaceuticals, Inc. Methods and compositions for inhibition of androgen receptor activity
KR20150127720A (ko) 2013-03-14 2015-11-17 유니버시티 오브 매릴랜드, 발티모어 안드로겐 수용체 하향 조절제 및 그의 용도
CA2920317A1 (en) 2013-08-12 2015-02-19 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
WO2015170336A1 (en) 2014-05-09 2015-11-12 Council Of Scientific & Industrial Research 16α-HETEROARYL PREGNENOLONE ACETATE AND A PROCESS FOR PREPARATION THEREOF
WO2016119742A1 (zh) * 2015-01-29 2016-08-04 苏州晶云药物科技有限公司 (3β)-17-(1H-苯并咪唑-1-基)雄甾-5，16-二烯-3-醇的盐及其制备方法
ITUA20164043A1 (it) * 2016-06-01 2017-12-01 Ind Chimica Srl Processo per la preparazione di 3β-idrossi-17-(1H-benzimidazol-1-il)androsta-5,16-diene
WO2017208132A1 (en) * 2016-06-01 2017-12-07 Industriale Chimica S.R.L. Process for the preparation of galeterone
CN112997256A (zh) * 2018-06-14 2021-06-18 阿斯利康(英国)有限公司 使用皮质类固醇医药组合物治疗和预防哮喘症状的方法
JP7648538B2 (ja) * 2019-04-27 2025-03-18 ヘルス リサーチ インコーポレイテッド 前立腺癌の治療のためのクマリン修飾アンドロゲン

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008536807A (ja) * 2005-03-02 2008-09-11 ユニバーシティ、オブ、メリーランド 新規なｃ−１７−ヘテロアリールステロイドｃｙｐ１７阻害剤／抗アンドロゲン：合成、インビトロ生物活性、薬物動態および抗腫瘍活性

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH621803A5 (https=) * 1974-08-08 1981-02-27 Siphar Sa
US5604213A (en) * 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
CA2161531A1 (en) * 1993-04-30 1994-11-10 Donald C. Malins Dna profiles as an indicator of cellular redox potential and cancer risk
US5994335A (en) * 1997-10-17 1999-11-30 The University Of Maryland, Baltimore 17-azolyl steroids useful as androgen synthesis inhibitors
US20030054053A1 (en) * 2001-09-20 2003-03-20 Charles Young Methods and compositions for inhibiting the proliferation of prostate cancer cells
JP4855253B2 (ja) 2003-07-29 2012-01-18 ドムペ・ファ．ル．マ・ソチエタ・ペル・アツィオーニ 幹細胞動員に有用な医薬の組み合わせ
JP4585201B2 (ja) * 2004-01-23 2010-11-24 丸善製薬株式会社 アンドロゲン受容体結合阻害剤、養毛剤、皮脂分泌抑制剤及び前立腺肥大抑制剤
WO2008154382A1 (en) 2007-06-06 2008-12-18 University Of Maryland, Baltimore Hdac inhibitors and hormone targeted drugs for the treatment of cancer
US20100048524A1 (en) * 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
WO2011017534A2 (en) 2009-08-07 2011-02-10 Tokai Pharmaceuticals, Inc. Treatment of prostate cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008536807A (ja) * 2005-03-02 2008-09-11 ユニバーシティ、オブ、メリーランド 新規なｃ−１７−ヘテロアリールステロイドｃｙｐ１７阻害剤／抗アンドロゲン：合成、インビトロ生物活性、薬物動態および抗腫瘍活性

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6014031817; Ｔａｄａｓ　Ｖａｓａｉｔｉｓ，　ｅｔ　ａｌ．: 'Ａｎｄｒｏｇｅｎ　ｒｅｃｅｐｔｏｒ　ｉｎａｃｔｉｖａｔｉｏｎ　ｃｏｎｔｒｉｂｕｔｅｓ　ｔｏ　ａｎｔｉｔｕｍｏｒ　ｅｆｆｉｃａｃｙ　ｏｆ　１７｛ａｌｐｈａ｝-ｈｙｄｒｏｘｙｌａｓｅ／１７，２０-ｌｙａｓ' Ｍｏｌ　Ｃａｎｃｅｒ　Ｔｈｅｒ ７（８）, 2008, ２３４８-５７ *

Also Published As

Publication number Publication date
US20110034428A1 (en) 2011-02-10
BR112012002797A2 (pt) 2019-09-24
US8791094B2 (en) 2014-07-29
EP2461814A2 (en) 2012-06-13
KR20120056267A (ko) 2012-06-01
WO2011017534A2 (en) 2011-02-10
CA2770092A1 (en) 2011-02-10
US20150166599A1 (en) 2015-06-18
US20140343024A1 (en) 2014-11-20
EP2461814A4 (en) 2012-12-05
WO2011017534A3 (en) 2011-06-30
JP2016074687A (ja) 2016-05-12
US20150203528A1 (en) 2015-07-23
US9156878B2 (en) 2015-10-13
US20170157148A1 (en) 2017-06-08
AU2010279398A1 (en) 2012-03-08

Similar Documents

Publication Publication Date Title
JP2016074687A (ja) 前立腺癌の処置
AU668434B2 (en) Combination therapy for prophylaxis and/or treatment of benign prostatic hyperplasia
US20160002283A1 (en) Novel compositions and methods for treating prostate cancer
TWI394571B (zh) 螺旋１２取向性之非類固醇抗雄激素及包含其之醫藥組合物、以及其等之用途
KR102606253B1 (ko) 2-(tert-부틸아미노)-4-((1r,3r,4r)-3-하이드록시-4-메틸사이클로헥실아미노)-피리미딘-5-카복사마이드의 제형
JP2004505061A (ja) うっ血性心不全の処置のための、エポキシ−ステロイド型アルドステロン拮抗薬とカルシウムチャンネル遮断薬の併用療法
KR20160058774A (ko) 안드로겐-표적 치료제를 이용하는 종양 질환 치료를 위한 바이오마커
JP2017535614A (ja) 疾患治療用の縮合二環式化合物
CN111479560A (zh) 用于治疗非转移性去势难治性前列腺癌的抗雄激素
AU2021255723A1 (en) Solid forms of an N-terminal domain androgen receptor inhibitor and uses thereof
US20020123485A1 (en) Epoxy steroidal aldosterone antagonist and beta-adrenergic antagonist combination therapy for treatment of congestive heart failure
JP2004507495A (ja) 認知機能改善のためのアルドステロン受容体拮抗薬の使用
JP2002515484A (ja) ２−フェニルインドール化合物およびエストロゲン製剤からなる組成物
JP2002543119A (ja) 環状尿素および環状アミド誘導体を用いた周期的管理
JP7526783B2 (ja) 癌を処置する方法
JP2002538172A (ja) 循環器疾患治療のためのアンギオテンシン変換酵素阻害薬およびエポキシ−ステロイドアルドステロン拮抗薬の組合せ療法
JP2020530026A (ja) 線維性疾患の治療における使用のための化合物及びその医薬組成物
JP2002543159A (ja) ベンズイミダゾロンとプロゲストゲンを含有する組成物
US10799478B2 (en) Treatment of androgen deprivation therapy associated symptoms
WO2024076633A1 (en) Methods of treating estrogen receptor-mediated disorders
JP2002543206A (ja) 環状尿素および環状アミド誘導体
HK1233508A1 (en) Treatment of androgen deprivation therapy associated symptoms

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130716

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130716

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140730

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141017

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141024

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141126

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150104

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150713

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151111

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20151222

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20160129